University of Oulu

Riina K. Ollikainen, Pyry H. Kotkaranta, Janette Kemppainen, Hanna-Riikka Teppo, Hanne Kuitunen, Risto Pirinen, Taina Turpeenniemi-Hujanen, Outi Kuittinen & Milla E.L. Kuusisto (2021) Different chemokine profile between systemic and testicular diffuse large B-cell lymphoma, Leukemia & Lymphoma, 62:9, 2151-2160, DOI: 10.1080/10428194.2021.1913150

Different chemokine profile between systemic and testicular diffuse large B-cell lymphoma

Saved in:
Author: Ollikainen, Riina K.1,2; Kotkaranta, Pyry H.1,2; Kemppainen, Janette1,2;
Organizations: 1Cancer and Translational Medicine Research Unit, University of Oulu, Oulu, Finland
2Department of Oncology and Radiotherapy and Medical Research Center, Oulu University Hospital, Oulu, Finland
3Department of Pathology, Oulu University Hospital, Oulu, Finland
4Department of Pathology, North Karelia Central Hospital, Joensuu, Finland
5Department of Oncology, Faculty of Health Medicine, Institute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland
6Department of Hematology, Oulu University Hospital, Oulu, Finland
Format: article
Version: accepted version
Access: embargoed
Persistent link: http://urn.fi/urn:nbn:fi-fe2021122162825
Language: English
Published: Informa, 2021
Publish Date: 2022-04-15
Description:

Abstract

Although treatment for diffuse large B-cell lymphoma (DLBCL) has taken some notable steps in the 2000s, there are still subgroups of patients suffering from high mortality and relapse rates. To further improve treatment outcomes, it is essential to discover new mechanisms of chemotherapy resistance and create new treatment approaches to overcome them. In the present study, we analyzed the expression of chemokines and their ligands in systemic and testicular DLBCL. From our biopsy sample set of 21 testicular and 28 systemic lymphomas, we were able to demonstrate chemokine profile differences and identify associations with clinical risk factors. High cytoplasmic CXCL13 expression had correlations with better treatment response, lower disease-related mortality, and limited stage. This study suggests that active CXCR5/CXCL13 signaling could overtake the CXCR4/CXCL12 axis, resulting in a better prognosis.

see all

Series: Leukemia & lymphoma
ISSN: 1042-8194
ISSN-E: 1029-2403
ISSN-L: 1042-8194
Volume: 62
Issue: 9
Pages: 2151 - 2160
DOI: 10.1080/10428194.2021.1913150
OADOI: https://oadoi.org/10.1080/10428194.2021.1913150
Type of Publication: A1 Journal article – refereed
Field of Science: 3122 Cancers
Subjects:
Funding: The authors extend our gratitude to Anne Ojala for her skillful assistance with immunostaining. The authors also thank the Väisänen Fund in the Terttu Foundation for personal research grants (RO, PK, JS) and for the research group grant (T.T-H).
Copyright information: © 2021 Informa UK Limited. This is an Accepted Manuscript version of the following article, accepted for publication in Leukemia & Lymphoma. Riina K. Ollikainen, Pyry H. Kotkaranta, Janette Kemppainen, Hanna-Riikka Teppo, Hanne Kuitunen, Risto Pirinen, Taina Turpeenniemi-Hujanen, Outi Kuittinen & Milla E.L. Kuusisto (2021) Different chemokine profile between systemic and testicular diffuse large B-cell lymphoma, Leukemia & Lymphoma, 62:9, 2151-2160, DOI: 10.1080/10428194.2021.1913150. It is deposited under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
  https://creativecommons.org/licenses/by-nc/4.0/